Radient Pharmaceuticals Corporation fka RXPC

[Gold Seeker]

Jimtash, even the combination test anticipated by GCDx does not have enough specificity to be a screening test. Using the numbers given by Gartner, even restricting the test to smokers, the national cancer seer data shows that for every 1000 tests given as a screen to smokers, 12 would actually have cancer, 1 would have cancer but not be detected. The big problem would be the 30 false positives. That is unacceptable and no approval will ever be given to a test with a ton more false positives than accurate tests. Also, if you select a higher sensitivity to include the inaccurate false negative, the specificity would plummet.

Gartner may be excited about the test because there are a ton of naive investors who would think the test would be fantastic just as you have stated. What Gartner is really excited about is the amount of money he can put in his pocket during the process.